Nutra Pharma Corp.
NPHC · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.02 | 0.01 | -0.02 |
| FCF Yield | -2.72% | -4.24% | -3.91% | -1.62% |
| EV / EBITDA | 17.70 | -34.59 | 2.97 | 9.79 |
| Quality | ||||
| ROIC | -6.54% | 5.44% | -60.46% | 3.91% |
| Gross Margin | 62.41% | 32.73% | 35.10% | -150.06% |
| Cash Conversion Ratio | -0.29 | 0.44 | -0.05 | -0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 73.28% | 27.46% | 6.88% | -2.17% |
| Free Cash Flow Growth | 41.95% | 9.93% | -32.89% | 43.01% |
| Safety | ||||
| Net Debt / EBITDA | 10.09 | -19.32 | 1.42 | 3.49 |
| Interest Coverage | 3.78 | -1.60 | 27.11 | -3.68 |
| Efficiency | ||||
| Inventory Turnover | 0.83 | 1.46 | 0.23 | 2.08 |
| Cash Conversion Cycle | -1,210.94 | -563.75 | -2,837.05 | 239.35 |